ABSTRACT: Sarcomas are associated with a high incidence of lung metastasis, which leads to a high-risk of cancer death. This study was performed to explore the pre-clinical theranostic potential of a novel fully functional recombinant vesicular stomatitis virus carrying imaging gene Katushka (rVSV-K), as virotherapy and circulating tumor cells (CTCs) detection in the syngeneic mouse model of osteosarcoma with spontaneous pulmonary metastases. Recombinant VSV-K was generated and evaluated in vitro on human and murine osteosarcoma cells. Spontaneous osteosarcoma metastases were established in immune-competent mice by implanting subcutaneously syngeneic osteosarcoma LM8 cells. The vector was injected into the tumor-bearing mice via jugular vein either once or repeatedly. To assess effectiveness, primary tumor growth and development of lung metastasis as well as survival were evaluated. We found that rVSV-K efficiently replicated in and killed all osteosarcoma cell lines in time-dependent manners. Both single or repeated systemic injections of the virus did not inhibit the growth of the primary tumor, but the repeated administration could effectively suppress the development of lung metastases and was likely responsible for the observed increase in survival. Furthermore, we demonstrated, for the first time, that CTCs in blood samples from syngeneic osteosarcoma-bearing mice were successfully detected by utilizing rVSV-K ex vivo. Our results show that repeated systemic injections of rVSV-K are an effective anti-metastatic agent against osteosarcoma in immune-competent mice and this virus to be a useful tool for detection of osteosarcoma CTCs, suggesting that further development of future viral-based theranostic approach in patients with osteosarcoma is warranted. ß
Sarcomas in general represent a rare, heterogeneous set of soft tissue and bone neoplasms of mesenchymal origin, accounting for 10% and 8% of cancers in adults and adolescents. 1 Despite being a relatively rare, sarcomas are particularly lethal, with 1550 and 4990 estimated deaths in the USA due to bone and soft tissue cancers, respectively, in 2017. 2 Sarcoma cells that detach themselves from primary tumor enter into circulatory system to develop new growth in the distant organ, with lungs being the most common metastatic site. 3, 4 Long-term survival of metastatic sarcoma can only be reached in a small number of patients, despite advancement in multimodal therapeutic approach. 4 Consequently, the development of a new therapeutic strategy, based on the utilization of a targeted approach to prevent metastasis, is required.
Improved understanding of viral tropism is allowing the application of distinct virus groups as novel anticancer agents. Recently, development have focused mainly on carcinoma models. 5 Proof of the principle that oncolytic virotherapy (OV) can promote an antisarcoma response have been described only in few preclinical studies. 6, 7 In addition to molecularly engineered DNA viruses such as adenovirus and herpes simplex virus, oncolytic RNA viruses are being developed for cancer treatments because of their inherent tumor specificity. This group of viruses includes vesicular stomatitis virus (VSV), 8 reovirus, 9 measles virus, 10 and poliovirus. 11 VSV is a negative-sense RNA rhabdovirus with extreme sensitivity to the interferon response, which provides VSV as a potent oncolytic agent for tumor cells with a defective interferon response but has no impact in normal cells. 12, 13 The oncolytic recombinant VSV carrying imaging genes, Katushka (rVSV-K) may represent a particularly attractive vector platform for viral-based theranostic agents (therapeutic and diagnostic), due to its natural oncolytic potential and inherent mechanism for tumor specificity.
Detection of circulating tumor cells (CTCs) as a measure of metastatic potential by the FDA approved CellSearch system depends on epithelial specific markers, and it therefore lacks the capability to detect CTCs in sarcoma due to the latter's mesenchymal origin. 14 The present study develops what we believe to be a feasible theranostic strategy of rVSV-K to selectively label sarcoma CTCs with fluorescence among millions of blood cells and to effectively suppress metastatic development in the experimental immune-competent osteosarcoma mouse model.
MATERIALS AND METHODS

Cell Lines and Culture Conditions
The mouse osteosarcoma cell line LM8 was obtained from the Cell Engineering Division of Riken BioResource Center (Tsukuba, Ibaraki, Japan). LM8 is a variant of a murine osteosarcoma cell line established by Asai et al. 15 according to Fidler's method. The human osteosarcoma cell lines MG-63 and Saos-2 were obtained from the American Type Culture Collection (ATCC; Manassas, VA). Cells were maintained in Dulbecco's modified Eagle medium (DMEM, Wako, Osaka, Japan) supplemented with 10% FBS (Gibco, Life Technologies, Grand Island, NY) and 1% penicillin-streptomycin (Wako) in a humidified atmosphere containing 5% CO 2 at 37˚C. The human bone marrow derived MSC (MSC701) from a donor (56-year-old male) during a hip operation was cultured in Mesenchymal Stem Cell Basal Medium (MSCBM TM ; Lonza Japan, Tokyo, Japan). Isolation and in vitro expansion of MSC were established as described previously. 16 BHK-21 cells (ATCC; CCL-10) used for construction and titration of VSV were maintained in DMEM (Wako) with 10% FBS (Gibco).
Virus Generation and Infection Assays
Recombinant VSV expressing Katushka or a far-red fluorescent protein (RFP) was generated using the established method of reverse genetics. 17 Briefly, the Katushka reporter gene was cloned into the XhoI and NheI sites of pVSV-XN2. The plasmid pVSV-XN2 contains the entire VSV genome sequence (Indiana serotype, GenBank Accession number NC_001560) flanked by the T7 promoter, and hepatitis delta ribozyme and T7 terminator (Fig. 1a) . The plasmid has the unique XhoI and NheI restriction sites between the G and L genes flanked by VSV transcription start and stop signals for insertion of an additional gene. 18 The resultant plasmid was then transfected into BHK-21 cells constitutively expressing the T7 RNA polymerase as well as the helper plasmids, pIRES-N, pIRES-P, and pIRES-L to establish a newly recombinant virus VSV-Katushka. 19 Viral titers of working stock (TCID 50 /ml) were determined by the standard TCID 50 assay using BHK-21 cells.
For virus infection assays, 3 Â 10 5 cells/well were incubated overnight in six-well plates and then infected with rVSV-K at 0, 0.01, or 1 multiplicity of infection (MOI). Twenty-four hours after infection, cells were evaluated for cytopathic effects by bright-field microscopy and RFP expression by fluorescence microscopy. In addition, cell culture supernatant of 0.01 MOI virus infection at designated time points was assayed for the viral RNA genome by real-time PCR using specific primers. All experiments were performed in triplicate.
Virus Replication Assays
Synthetic genomic VSV RNA was transcribed from the fulllength pVSV-XN2 by using the RiboMAX Large Scale RNA Production System-T7 (Promega, Madison, WI) according to the manufacturer's instructions. Following purification, the concentration of RNA was determined by a spectrophotometer and used to generate a standard curve for real-time absolute quantification. Cells were infected with rVSV-K. Virus RNA was extracted according to the manufacturer's instructions from 140 ml of supernatant by using the QIAamp Viral RNA kit (Qiagen, Hilden, Germany) and was subsequently reverse-transcribed (QuantiTect 
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In Vitro Cytotoxicity Assays Cells were seeded into 96-well plates at 4 Â 10 3 cells/well overnight with a volume of 100 ml and then infected with rVSV-K at an MOI of 0.01. A Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) based on WST-8 was used to measure the cell viability at designated time points after infection according to the manufacturer's recommendations. The absorbance was measured at 450 nm by a Model 680 Microplate Reader (Bio-Rad, Hercules, CA). Cell viability was expressed as a percentage of viable cells compared to mock-infected control cells. Three independent experiments were performed.
Animal Studies
All procedures involving animals were approved by Hiroshima University's Ethics Committee for Experimental VESICULAR STOMATITIS VIRUS ON OSTEOSARCOMA Animals and were performed in strict accordance with this committee's guidelines. Experiments were performed on C3H male mice (5-6 weeks of age; Shimizu, Kyoto, Japan), into whose backspace 1 Â 10 7 highly metastatic LM8 murine osteosarcoma cells (suspended in 100 ml DMEM) were implanted subcutaneously into the backspace on day 0. Primary tumors with a mean of 5 mm were palpable on day 7. Sarcoma-bearing mice were assigned at random to four different treatment groups (n ¼ 6 per group): the rVSV-K consecutive intravenous (rVSV-K-CIV) treatment group, the rVSV-K single intravenous (rVSV-K-SIV) treatment group, and two control groups. Each sarcoma-bearing animal of the rVSV-K-CIV group received repeated intravenous injections (rVSV-K, 0.5 Â 10 7 pfu/100 ml) through the jugular vein at day 7, 14, 21, and 28 (once a week for four consecutive weeks) after tumor implantation, while its corresponding control group, control-CIV, received an equivalent volume of buffer. In the rVSV-K-SIV group, mice received a single intravenous injection (rVSV-K, 0.5 Â 10 7 pfu/100 ml via jugular vein) at day 7 after tumor implantation, whereas in the control-SIV group an equivalent volume of buffer was injected intravenously. To assess the primary tumor and metastatic response to treatment, tumor growth was evaluated by measuring the tumor volume (mm 3 ) weekly. At 5 weeks after tumor implantation, the animals were sacrificed and their lung tissue was harvested to perform histological analysis. In a separate experiment, the survival of the three animal groups was followed.
Detection of CTCs by the rVSV-K Assay
The metastatic osteosarcoma syngeneic mouse model was provided by utilizing 1 Â 10 7 LM8 cells inoculated subcutaneously in the backspace. Five weeks after inoculation in which pulmonary metastases were found, 15 mice were anesthetized with 1% isoflurane and blood samples (500 ml) were collected from the jugular vein into EDTA tubes (BD Bioscience, Tokyo, Japan) using a 29-G needle. Blood collected was then subjected to RBC Lysis using 1Â RBC lysis buffer (eBioscience, San Diego, CA) according to the manufacturer's instructions. Virus stock was diluted in DMEM supplemented with 10% fetal bovine serum and antibiotic to yield a concentration of 1 Â 10 7 plaque forming unit (pfu)/ml. Nucleated cells from whole blood following red blood cell lysis were resuspended in 1 ml of the diluted virus and incubated at 37˚C for 24 h. The cells were then stained with DAPI and anti-mouse CD45-FITC (Miltenyi Biotech, Germany) and subsequently deposited onto glass slides using the Smear Gell kit (GenoStaff, Tokyo, Japan) according to the manufacturer's instructions. Images ware captured and recorded with the BZ-9000 Biorevo fluorescence microscope (Keyence Corporation, Osaka, Japan).
Histological Analysis
At 5 weeks after tumor implantation into the four treatment groups, the animals were sacrificed. Explanted lungs were fixed in 4% paraformaldehyde overnight and were then paraffin embedded. Five-micrometer (5 mm) sections were subjected to hematoxylin and eosin (H&E) staining. Digital images from lung sections of each animal (n ¼ 6 per group) were obtained with a Keyence BZ-9000 microscope, which allowed the composition of merged images captured at 4Â objective, with automatic focus correction. The metastatic burden was quantified by determining the area occupied by tumor nodules using BZ-II Analyzer Software ver.1.42. (Keyence Corporation) and by normalizing the tumor nodule area to the total lung section area. Four non-adjacent lung tissue sections were analyzed per animal and averaged for graphic representation.
Statistical Analysis
Primary tumor volume based on caliper measurements was calculated by using the modified ellipsoidal formula: volume (mm 3 ) ¼ 1/2(length Â width 2 ). Student's t-test was used to evaluate differences in primary tumor growth and lung metastasis formation between the corresponding groups. Survival curves of animals treated with the VSV vector and of the control group were plotted according to the KaplanMeier method. Statistical significance in the different groups was compared using the log-rank test analysis. All results were processed using SPSS statistical software (version 22 for windows SPSS). Values are expressed as means AE SD, and statistical significance is defined as p < 0.05.
RESULTS
Oncolytic Activities of rVSV-K In Vitro
The replication-selective antitumor potential of rVSV-K was examined by RT-PCR. The results showed that rVSV-K was completely able to replicate its RNA genome in human and mouse osteosarcoma cells within 48 h after infection, whereas its RNA replication was considerably attenuated in normal bone marrow stromal cells (Fig. 1b) . Twenty-four hours after being infected with rVSV-K at a low MOI of 0.01, the osteosarcoma cells showed typical cytopathic effects, detaching themselves from the plate, whereas the morphology of normal bone marrow stromal cells infected with the virus as high as 1 MOI remained unchanged. Infected osteosarcoma cells also constantly expressed RFP at the same time (Fig. 2a) , but no expression was found in infected stromal cells (data not shown). These data demonstrated that rVSV-k has the inherent ability to preferentially infect and kill osteosarcoma cell lines.
In addition, we examined if 0.01 MOI rVSV-K infection would result in efficient cell killing in human and mouse osteosarcoma cells. The rVSV-K efficiently killed tumor cells in a time-dependent manner for up to 60 h, whereas normal MSC701 cells were refractory. Almost 100% of tumor cells were eradicated by the rVSV-K infection after 72 h (Fig.  2b) . The extent of viral killing to human osteosarcoma cell lines was nearly identical to that of the mouse osteosarcoma cell line, which was used in subsequent in vivo study.
In Vivo Therapeutic Efficacy of rVSV-K In order to elucidate the potential of rVSV-K as a therapeutic agent for osteosarcoma, we analyzed the virus in the immune-competent syngeneic osteosarcoma mouse model. The tumor growth rates of all groups (four groups; n ¼ 6 per group) were measured every week after tumor cell implantation and we found that neither of the r-VSV-K-treated groups showed any significant decrease (p > 0.05; Fig. 3 ) in tumor volumes compared with the control groups. These data suggest that neither a single nor repeated systemic injection of rVSV-K has the potential to induce antitumor effects on the primary tumor.
To demonstrate further the virus-mediated suppression of metastasis, we obtained histopathological sections showing the formation of metastasis in the lungs. Both r-VSV-K-treated groups (n ¼ 6 per group) displayed a reduction in the number of metastatic lung foci compared to the vehicle-treated mice (Fig.  4a) . Further quantification of lung metastasis by image analysis in histological sections confirmed that the ratio of tumor area/normal lung area in the rVSV-K-CIV group was decreased significantly compared to that of the control-CIV group (n ¼ 6; p < 0.01), whereas in the rVSV-K-SIV group this ratio was not significantly decreased compared to that of the control-SIV group (p ¼ 0.331; Fig. 4b ). The results confirmed the notion that there was remarkable lung metastatic suppression associated with repeated intravenous injection of rVSV-K.
In a separate experiment, sets of animal (four groups; n ¼ 6 per group) were followed to assess survival (Fig. 5) . The Control-CIV mice started to die of tumor progression in 33 more days and all of them expired at 44 days (median survival, 38 days). The rVSV-K-CIV group survived up to 60 days post tumor inoculation (median survival, 52 days) and the differential survival rates were statistically significant according to log-rank test analysis (p < 0.01). On the other hand, the rVSV-K-SIV group survived up to 50 days post tumor inoculation (median survival, 41 days), whereas the control-SIV group survived up to 43 days post tumor inoculation (median survival, 36 days) and the differential survival rates were not statistically significant (p ¼ 0.073). These data suggest that enhancement of oncolytic activity may indeed be mediated by repeated intravenous injection of rVSV-K.
Ex Vivo CTC Detection by rVSV-K Assay
The volume of 0.5 ml of a whole blood sample from the mouse syngeneic model of osteosarcoma was analyzed using an rVSV-K ex vivo infection assay. The anti-CD45 antibody used in this present study covered the detection of WBC. Microscopically, infected cells (CTCs) were larger than the surrounding CD45 þ immune cells, showing very strong red fluorescent expression, containing nuclei (DAPI þ ) and were CD45 -, hence they were not leucocytes (Fig. 6) . Our results suggested the feasibility of the rVSV-K assay to detect CTCs in a blood sample from the sarcoma mice model.
DISCUSSION
The present study demonstrates that rVSV-K was efficiently replicated in vitro in murine and human osteosarcoma cell lines and led to RFP expression in two-dimensional (2D) cell cultures. However, its capability to do so is attenuated in the normal human mesenchymal stem cells. VSV is a potent trigger of antiviral response, interferon (IFN) mediated, in normal tissue. 8 Osteosarcoma cells were found to have a lack of ability to induce secretion of interferon b, an innate antiviral response. 20 Therefore, rVSV-K could selectively replicate in and kill osteosarcoma cells. However, it is noteworthy that a recent report indicated osteosarcoma cells grown in in threedimensional (3D) culture are less susceptible to the VESICULAR STOMATITIS VIRUS ON OSTEOSARCOMA oncolytic adeno-associated virus than in 2D. 21 The reason for this reduction of permissiveness may be due to alteration in cell membrane receptors in differentiated cells in 3D culture. 21 Furthermore, multicellular tumor spheroid formations in 3D cultures allow for a difference in proliferative rates as well as oxygen tension between the surface and the interior bodies which better mimic tumor in vivo than conventional 2D cultures. 22 Despite these recent advances, the lack of standardized culture models and the reference methods to evaluate treatment effectiveness for 3D models as well as the simplicity of 2D models are the reasons why the model of choice is not regularly determined by a specific process of interest. [22] [23] [24] However, further studies with 3D culture models need to be considered to support the findings produced in the present study in order to ascertain the efficacy of rVSV-K in various osteosarcoma cell lines.
Osteosarcoma mouse models are often used for preclinical testing in the development of new therapeutic drugs. Among several models that have been established, the syngeneic LM8 model is one of the most commonly used. In this study, primary tumor formation was induced by injecting the LM8 cells ectopically into subcutaneous tissue. Subcutaneous tumor implantation is frequently used because it is technically less demanding to perform and easier to monitor tumor progression when compared with intrabone implantation. Despite evidence that orthotopic implantation of some osteosarcoma cell lines can promote progression and metastasis more efficiently due to original microenvironment than ectopic subcutaneous implantation, the LM8 cells have been shown to develop lung metastasis with an incidence of 100% even after subcutaneous implantation. 15 This cell line has a high expression of matrix metalloproteinases (MMPs) 2, MMPs 9, b catenin, nuclear factor-kappa B (NF-kB), and vascular endothelial growth factor (VEGF) which may explain its elevated metastatic potential. 15 While this subcutaneous osteosarcoma mouse model may serve as a simple yet interesting system to explore new agents against primary tumor and pulmonary metastasis, it is important to understand the limitations of this model for studying the efficacy of the novel agents in the treatment of osteosarcoma with a microenvironment of the organ of origin, which allows the development of these tumor cells with biological and metastatic properties resembling clinical situations. It has been recently observed that a large genomic heterogeneity exists between osteosarcoma patients so that individualized precision therapy is needed in the management of osteosarcoma. 25 In order to achieve this purpose, the patientderived orthotopic xenograft (PDOX) mouse models for osteosarcoma has been established in some laboratories. [26] [27] [28] [29] Although the perceived technical complexity and the appropriate quality control needed to optimize the viability of the original human tumor cells, such PDOX models can play an important role for individualized therapy approaches in translational research as they are more closely recapitulate the heterogeneity of primary human osteosarcoma. 26, 28 In our study, we showed suppression of spontaneous metastasis to the lungs with the repeated systemic administrations of rVSV-K in a syngeneic ectopic murine LM8 osteosarcoma mouse model. These findings called for further studies using other osteosarcoma mouse model, including PDOX model, in order to better characterize the potential role of VSV in virotherapy of metastasis osteosarcoma.
Oncolytic virotherapy is an emerging treatment modality for treating cancer patients. 30 Recent studies have indicated that consideration of the host immune system is important regarding the route of administration by the systemic delivery. In the present study, we found that a systemic intravenous injection of rVSV-K could not achieved potent antitumor efficacy in primary tumor growth. The virus can be quickly curtailed systemically by a complement cascade and neutralizing antibody. 31, 32 In addition to modification of VSV through the incorporation of cytokine into the viral genome, combination approaches either with adoptive cell therapy (T cells) or immune checkpoint inhibition (PD-L1 blockade) are developed to achieve a much improved oncolytic effect on the primary tumor. [33] [34] [35] Although established immunity against viral antigens may compromise oncolytic efficacy, VSV has been observed to induce the immune responses including the activation of CD8 þ T cells and natural killer (NK) cells that are important for the restriction of the metastatic outgrowth of cancer cells. [36] [37] [38] [39] Recently, NK cells have been observed to possess the feature of robust recall response upon subsequent challenge with VSV. 40, 41 Our results showed that, relative to the corresponding control groups, when a single dose of rVSV-K was given intravenously, the metastasis inhibition to the lung, as well as the survival study, was not statistically significant. Interestingly, repeated systemic administration of rVSV-K significantly suppressed lung metastasis and was likely responsible for the observed increase in survival. This difference may suggest that whereas host antibodies can limit the effectiveness of the systemic injections, it is possible that reactivity of innate immune response, NK cells, particularly upon sequential exposure to rVSV-K on the repeated intravenous treatment group, could still have contributed to the suppression of metastasis.
Recent studies demonstrated that recombinant VSV was both nonpathogenic and non-transmissible in a susceptible species and had been used in healthy adults in clinical trials of Ebola virus vaccines without serious adverse effects. These findings support further clinical development of oncolytic VSV as a safe therapeutic treatment for human osteosarcoma. [42] [43] [44] Many platforms have been developed on the basis of biological properties and physical properties in the detection CTCs for cancer diagnosis.
14,45 Because VESICULAR STOMATITIS VIRUS ON OSTEOSARCOMA sarcoma is derived from mesenchymal origin, detection using the FDA approved approach (EpCAM) may not be optimal. Nevertheless, alternative markers such as vimentin and studies using RT-PCR, have aided the detection of CTC in sarcoma patients. [46] [47] [48] Possible biological hurdles in those methods may include expression of a variety of cell surface markers or the uncertainty of the exact cellular origin of RT-PCR products, whether they are derived from live or dead cells. Moreover, studies have demonstrated the ability of the DNA virus (telomerase-dependent adenovirus) to detect carcinoma CTC, the tumor specificity of which depends on nuclear transcription factors. 49 Our research is the first to highlight sarcoma CTC detection by RNA virus, which is not subject to the influence of nuclear transcription factors.
In the present study, we demonstrated a novel osteosarcoma CTCs detection assay which was not dependent on surface molecule expression but the inherent specificity of live tumor cells. The assays relied on the recombinant vesicular stomatitis virus vector expressing Katushka driven by defective antiviral interferon signaling pathways in tumor cells. The TurboFP635 (Katushka) gene combines far-red emission and brightness features of a fluorescent protein, characterized by high pH-stability and photostability. 50 These features are necessary for visualization of living cells thus making them a powerful instrument for the visual detection of CTCs. Cells infected with rVSV-K were confirmed to be CTCs, as characterized by their high far-red fluorescent brightness with a blue fluorescent nucleic acid stain as well as their negative selection using antibodies against CD45. Detection of osteosarcoma CTCs with rVSV-K removes bias related to the use of antibodies and thus potentially detects CTCs of various tumor types, not limited to those of osteosarcoma origin.
In conclusion, osteosarcoma presenting metastatic disease remains a major problem with limited treatment options. Here, we show that repeated systemic injections of rVSV-K is an effective anti-metastatic agent against osteosarcoma in immune-competent mice and this virus to be a useful tool for detection of osteosarcoma CTCs, suggesting that further development for future viral-based theranostic approach in patients with osteosarcoma is warranted. 
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